Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open, Phase IV, Single-group, Multicentre Study to Assess the Long-term Persistence of Antibodies Against Hepatitis B and the Immune Response to a Hepatitis B (HBV) Vaccine Challenge in Children Aged 7-8 Years of Age and Previously Vaccinated in Infancy With GSK Biologicals' HBV Vaccine (Engerix™-B).

NCT00519649 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00519649
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00519649 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open, Phase IV, Single-group, Multicentre Study to Assess the Long-term Persistence of Antibodies Against Hepatitis B and the Immune Response to a Hepatitis B (HBV) Vaccine Challenge in Children Aged 7-8 Years of Age and Previously Vaccinated in Infancy With GSK Biologicals' HBV Vaccine (Engerix™-B).
Lead sponsor
GlaxoSmithKline
Phase
Phase 4
Overall status
Completed
Start date
August 31, 2007
Completion date
December 31, 2007
Enrollment
301 (actual)
Sites
35

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis b vaccine